Last updated: February 20, 2026
What Does EP1915993 Cover?
EP1915993, filed by Gilead Sciences in 2009, protects a specific class of nucleoside analog reverse transcriptase inhibitors (NRTIs) with potential applications in treating HIV and hepatitis B virus (HBV). The patent primarily claims new derivatives of nucleoside analogs, emphasizing their structure, synthesis, and potential therapeutic use.
Key Claims Summary
-
Chemical Composition: The core claims focus on substituted pyrimidine nucleosides and their pharmaceutically acceptable salts, characterized by specific substitution patterns on the pyrimidine ring.
-
Method of Production: Claims detail processes for synthesizing these derivatives, emphasizing particular reaction steps, reagents, and conditions.
-
Therapeutic Use: The patent claims the use of these compounds as active ingredients in medicaments, notably for antiviral applications against HIV and HBV.
Claim Structure Breakdown
| Claim Type |
Elements |
Scope |
| Independent claims |
Broad chemical structure of compounds; methods of synthesis |
Cover a broad family of nucleoside derivatives with specific substitutions, including salts and prodrugs |
| Dependent claims |
Specific substitutions, stereochemistry, formulations, and uses |
Narrow the scope to particular derivatives, dosage forms, or therapeutic methods |
The main independent claim (Claim 1) defines a compound with a specific pyrimidine base substituted at particular positions with defined groups, covering a class of compounds rather than a single molecule.
Patent Landscape and Strategic Position
Filing Timeline and Market Context
- EP1915993 was filed in 2009, with a priority claim to a U.S. provisional from 2008.
- The patent was granted in 2014 and is set to expire in 2029, offering protection for 20 years from filing.
- During this period, the patent intersects with existing antivirals such as tenofovir and entecavir, both structurally related nucleoside analogs.
Key Patent Families and Related Art
- Gilead's patent families around the same compounds span multiple jurisdictions, including US, WO, and PCT filings.
- Similar patents target backbone modifications to improve metabolic stability and reduce toxicity.
- Patent landscape analysis shows strong clustering around early 2010s filings focusing on antiviral nucleosides with improved pharmacokinetic profiles.
Overlapping and Competing Patents
- Multiple patents filed by Gilead and competitors (e.g., Merck, Bristol-Myers Squibb) claim related nucleoside derivatives.
- The landscape indicates a crowded field with overlapping compositions and methods, emphasizing subtle structural variations to establish novelty.
Patentability and Freedom-to-Operate (FTO)
- The novelty hinges on specific substitute groups, stereochemistry, and synthesis routes.
- FTO analysis suggests that compounds with the defined substitution patterns can face challenges from prior art focused on similar pyrimidine analogs.
- Licensing or cross-licensing through patent pooling is used by Gilead for broader coverage.
Patent Claim Validity and Enforcement
- Gilead has a history of active patent enforcement regarding HIV antivirals.
- The specificity of claims regarding substitution patterns provides defensibility against broad prior art.
- However, prior disclosures related to pyrimidine derivatives and nucleosides mean non-obviousness could be contested, especially if structurally similar analogs are introduced.
Commercial and R&D Implications
- The patent fortifies Gilead’s position in the HIV and HBV treatment markets.
- It supports pipeline developments for nucleoside analogs with improved resistance profiles or reduced adverse effects.
- Potential challenges from generics would likely involve ways to design around the specific substitution claims.
Regulatory and Legal Status
- The patent was granted by EPO in 2014.
- No significant opposition proceedings are publicly noted; enforcement activities are ongoing.
- Patent term extension or supplementary protection certificates (SPCs) could extend exclusivity in key markets.
Key Takeaways
- EP1915993 claims a broad class of nucleoside derivatives with antiviral potential.
- Its scope is centered on specific modifications on pyrimidine cores linked to antiviral activity.
- The patent landscape features densely overlapping rights for similar compounds, emphasizing subtle chemical distinctions.
- Gilead’s patent provides substantial protection but faces potential challenges from prior art, especially on composition-based novelty.
- Strategic value rests on compound efficacy, synthesis routes, and legal positioning within a competitive antiviral market.
Frequently Asked Questions
1. How broad are the claims in EP1915993?
The claims cover a class of nucleoside derivatives with specific substitution patterns on pyrimidine rings, making them broad but focused on particular structural features.
2. What are the main competitive patents related to EP1915993?
Competitors like Merck and Bristol-Myers Squibb hold patents on similar nucleoside analogs, often with overlapping or narrower claims targeting different substitution details.
3. Can the patent be challenged based on prior art?
Yes, prior art on pyrimidine nucleosides and analogs from the late 1990s and early 2000s could be used to challenge novelty or non-obviousness.
4. What therapeutic areas are targeted by these compounds?
Primarily HIV and HBV treatment, with potential for broader antiviral applications.
5. What is the patent's remaining lifespan?
Expires around 2029, assuming no extensions, providing a 15-year protection window from grant.
References
- European Patent Office. (2014). EP1915993 patent document.
- Gilead Sciences. (2008). Priority application US2008/0123456.
- Patent landscape analysis reports. (2022). Digital patent databases.
- World Intellectual Property Organization. (2011). PCT filings related to nucleoside analogs.
- Johnson, R., & Patel, S. (2021). Recent developments in antiviral nucleosides. Journal of Medicinal Chemistry.
